These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 35987855)
1. [Prevention and management of pegaspargase associated-toxicities (excluding coagulation abnormalities). Recommendations of the French Society of Children and Adolescent Cancers (Leukemia committee)]. Poirée M; Neumann F; Thomas C; Simon P; Lunven AFR; Plantaz D; Doulet ST; Strullu M Bull Cancer; 2022 Nov; 109(11):1125-1131. PubMed ID: 35987855 [TBL] [Abstract][Full Text] [Related]
4. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia. Lau KM; Saunders IM; Goodman A J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860 [TBL] [Abstract][Full Text] [Related]
5. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia]. Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393 [TBL] [Abstract][Full Text] [Related]
13. Toxicity study of pegaspargase. Ettinger LJ; Lerner ED; Manglani MV Indian Pediatr; 2000 Jun; 37(6):631-6. PubMed ID: 10869143 [No Abstract] [Full Text] [Related]
14. Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia. Kaminski KS; Beach CL; Peden DB; Le U; Roehrs PA J Oncol Pharm Pract; 2016 Apr; 22(2):354-6. PubMed ID: 25567519 [TBL] [Abstract][Full Text] [Related]
15. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395 [TBL] [Abstract][Full Text] [Related]
16. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia. Daley RJ; Rajeeve S; Kabel CC; Pappacena JJ; Stump SE; Lavery JA; Tallman MS; Geyer MB; Park JH Leuk Lymphoma; 2021 Jan; 62(1):176-184. PubMed ID: 32985296 [TBL] [Abstract][Full Text] [Related]
17. Pegaspargase-induced pancreatitis. Alvarez OA; Zimmerman G Med Pediatr Oncol; 2000 Mar; 34(3):200-5. PubMed ID: 10696127 [TBL] [Abstract][Full Text] [Related]
18. [Advances on the role of pegaspargase in the treatment of childhood leukemia]. Liu L; Xie XT Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909 [TBL] [Abstract][Full Text] [Related]
19. Pegaspargase: an alternative? Holle LM Ann Pharmacother; 1997 May; 31(5):616-24. PubMed ID: 9161659 [TBL] [Abstract][Full Text] [Related]
20. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]